Analysis of affordability of the first line antihypertensive drugs for the ukrainian patients

L. V. Iakovlieva, M. M. Portyanka


Hypertension is one of the major medical and social problems in our country and around the world due to its significant prevalence and serious consequences, and this fact has determined the object and the aim of our study. The aim of the study was to determine affordability of the first line antihypertensive drugs recommended by the Unified Clinical Protocol of Medical Care to Patients with Hypertension (UCPMC) and presented at the pharmaceutical market of Ukraine in 2013-2014 for the Ukrainian patients. Two indicators were used to characterize the level of affordability of antihypertensive drugs: Ca.s and A. Ca.s determines the percentage of the average wage to be paid by the patient for the price of 1 package of a drug, and the greater value it has, the less affordable is the drug. The affordability ratio A shows the relationship between the growth of the living wage based on the index of growth of the drug price and the increase in the minimum wage. The study has revealed that the first line antihypertensive drugs (TNs) on the basis of 36 INNs and 35 fixed combinations were presented at the Ukrainian pharmaceutical market in 2013 and 2014. In 2014 the increase in the value of Ca.s for all INNs and all combinations was observed. It indicates the tendency towards decrease in affordability of drugs. However, by the absolute value most of Ca.s values are still in the range of highly affordable drugs, and it is provided by the presence of a great number of generic drugs at the market. The dynamics of A values has also confirmed the tendency towards decrease in affordability of antihypertensive drugs and their combinations. For example, 9 INNs and 5 combinations had A < 1 in 2013, and 32 INNs and 28 combinations – in 2014. This tendency of decrease in affordability of drugs necessitates introduction of socioeconomic measures to support the impoverished population of Ukraine; these measures may include reimbursement of expenditures on antihypertensive therapy at the expense of the state.


hypertension; coefficient of the solvency adequacy; affordability ratio; unified clinical protocol

Full Text:



Дослідницько-пошукова система «Лекарственные средства» компанії «Моріон». Дані за 20132014 рр.

Загородний М.І., Свінціцький А.С., Казак Л.І. та ін. Рациональная фармакотерапия. – К.: Національний медичний університет ім. О.О.Богомольця. – С. 502.

Налетов С.В., Зупанец И.А., Бахтеева Т.Д. и др. Клиническая фармакология: Учеб. пособие. – Х.: НФАУ, 2005. – 448 с.

Мазур Н.А. Основы клинической фармакологии и фармакотерапии в кардиологии. – М.: Медицина, 1992. – 304 с.

Свищенко Е.П., Коваленко В.Н. Артериальная гипертензия: Практическое руководство / Под ред. В.Н.Коваленко. – К.: МОРИОН, 2001. – 528 с.

Укрстат. Режим доступу: http: //

Уніфікований клінічний протокол надання медичної допомоги хворим з артеріальною гіпертензією. – К., 2012. – 61 с.

Яковлева Л.В., Бездетко Н.В., Герасимова О.А. и др. Фармакоэкономика: Учеб. пособие / Под ред. проф. Л.В.Яковлевой. – Х.: Изд-во НФаУ, 2009. – 158 с.

GOST Style Citations


Abbreviated key title: Klìn. farm.

ISSN 2518-1572 (Online), ISSN 1562-725X (Print)